
Greta Ali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2039862/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>ALK</i> Rearrangement in a Large Series of Consecutive Nonâ€"Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment. Archives of Pathology and Laboratory Medicine, 2014, 138, 1449-1458.	1.2	93
2	microRNA classifiers are powerful diagnostic/prognostic tools in <i>ALK-</i> , <i>EGFR-</i> , and <i>KRAS</i> -driven lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14924-14929.	3.3	74
3	Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations. Journal of Thoracic Oncology, 2019, 14, 1651-1661.	0.5	73
4	Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E288-E296.	1.8	71
5	Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features. International Journal of Oncology, 2013, 43, 765-774.	1.4	53
6	CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E528-E536.	1.8	49
7	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical Cancer Research, 2017, 23, 4312-4322.	3.2	41
8	Different estrogen receptor β expression in distinct histologic subtypes of lung adenocarcinoma. Human Pathology, 2008, 39, 1465-1473.	1.1	40
9	Anaplastic lymphoma kinase gene rearrangements in cytological samples of non–small cell lung cancer: Comparison with histological assessment. Cancer Cytopathology, 2014, 122, 445-453.	1.4	40
10	Tryptase Mast Cells in Malignant Pleural Mesothelioma as an Independent Favorable Prognostic Factor. Journal of Thoracic Oncology, 2009, 4, 348-354.	0.5	37
11	Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. European Journal of Pharmacology, 2009, 619, 8-14.	1.7	35
12	Effect of mesenchymal stem cell penile transplantation on erectile signaling of aged rats. Andrologia, 2010, 42, 187-192.	1.0	35
13	Analysis of Fusion Genes by NanoString System: A Role in Lung Cytology?. Archives of Pathology and Laboratory Medicine, 2018, 142, 480-489.	1.2	33
14	Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo. Neoplasia, 2011, 13, 217-IN3.	2.3	31
15	Malignancies Within Rhinophyma: Report of Three New Cases and Review of the Literature. Aesthetic Plastic Surgery, 2012, 36, 396-405.	0.5	31
16	Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma. Oncogene, 2015, 34, 1679-1687.	2.6	31
17	Rippling muscle disease and facioscapulohumeral dystrophy-like phenotype in a patient carrying a heterozygous CAV3 T78M mutation and a D4Z4 partial deletion: Further evidence for "double trouble― overlapping syndromes. Neuromuscular Disorders, 2012, 22, 534-540.	0.3	28
18	Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis. Oncotarget, 2017, 8, 2758-2770.	0.8	26

Greta Ali

#	Article	IF	CITATIONS
19	Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. Oncology Reports, 2009, 22, 683-91.	1.2	25
20	Differential Expression of Extracellular Matrix Constituents and Cell Adhesion Molecules between Malignant Pleural Mesothelioma and Mesothelial Hyperplasia. Journal of Thoracic Oncology, 2013, 8, 1389-1395.	0.5	25
21	Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. Cancer Letters, 2017, 411, 35-43.	3.2	25
22	P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value. Oncology Letters, 2015, 9, 449-453.	0.8	24
23	Activation of Type I and Type II Interferon Signaling in SARS-CoV-2-Positive Thyroid Tissue of Patients Dying from COVID-19. Thyroid, 2021, 31, 1766-1775.	2.4	24
24	Expression of p-AKT and p-mTOR in a large series of bronchopulmonary neuroendocrine tumors. Experimental and Therapeutic Medicine, 2011, 2, 787-792.	0.8	23
25	Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review. Journal of Thoracic Disease, 2018, 10, S342-S352.	0.6	23
26	Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours. Oncology Reports, 2012, 28, 1559-1566.	1.2	19
27	p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 520-527.	0.5	19
28	Glomus tumor of the shoulder: A case report and review of the literature. Oncology Letters, 2013, 6, 1021-1024.	0.8	19
29	P2X7 protein expression and polymorphism in non-small cell lung cancer (NSCLC). Journal of Negative Results in BioMedicine, 2014, 13, 16.	1.4	15
30	EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. Oncology Reports, 2016, 36, 1166-1172.	1.2	15
31	Expression of endothelin 1 and its angiogenic role in meningiomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 546-553.	1.4	14
32	Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. Biochemical Pharmacology, 2019, 164, 94-105.	2.0	14
33	An "inflammatory―mitochondrial myopathy. A case report. Neuromuscular Disorders, 2013, 23, 907-910.	0.3	13
34	Prevalent cardiac phenotype resulting in heart transplantation in a novel LMNA gene duplication. Neuromuscular Disorders, 2010, 20, 512-516.	0.3	12
35	Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer. Pharmacological Research, 2020, 158, 104920.	3.1	12
36	Expression of Cyclooxygenase-2 and Its Correlation with Vasogenic Brain Edema in Human Intracranial Meningiomas. Cancer Investigation, 2007, 25, 555-562.	0.6	11

Greta Ali

#	Article	IF	CITATIONS
37	Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. Scientific Reports, 2019, 9, 3536.	1.6	11
38	Myopathic Involvement and Mitochondrial Pathology in Kennedy Disease and in Other Motor Neuron Diseases. Current Molecular Medicine, 2014, 14, 598-602.	0.6	11
39	EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: A case report. Lung Cancer, 2013, 81, 297-301.	0.9	10
40	Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience. Lung Cancer, 2019, 138, 27-34.	0.9	10
41	Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything?â~†. Interactive Cardiovascular and Thoracic Surgery, 2010, 10, 572-576.	0.5	8
42	KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung. Lung Cancer, 2013, 81, 377-381.	0.9	8
43	Discordant somatic and germline <i>VECF-A</i> genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis. Pharmacogenomics, 2009, 10, 1225-1229.	0.6	7
44	Pseudodiverticula of Ureter: Radiologic and Histologic Findings. Urology, 2009, 73, 268-269.	0.5	7
45	Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. Neuromuscular Disorders, 2012, 22, 767-770.	0.3	7
46	Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report. Oncology Letters, 2015, 9, 1537-1540.	0.8	7
47	Histo ytological diagnostic accuracy in lung cancer. Cytopathology, 2014, 25, 404-411.	0.4	5
48	Mediastinal dedifferentiated liposarcoma. Acta Cardiologica, 2017, 72, 499-500.	0.3	4
49	Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy. Expert Review of Anticancer Therapy, 2021, 21, 887-900.	1.1	4
50	Laser capture microdissection: A tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. International Journal of Molecular Medicine, 2009, 24, 473-9.	1.8	3
51	A Single mtDNA Deletion in Association with a LMNA Gene New Frameshift Variant: A Case Report. Journal of Neuromuscular Diseases, 2022, 9, 457-462.	1.1	2
52	Inflammatory myopathy in a patient with postural and kinetik tremor. Neurological Sciences, 2011, 32, 1175-1178.	0.9	1
53	Single lymph node metastasis 10Âyears after radical resection of a thymoma. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, e11-e13.	0.4	1
54	Anti-HMGCR antibodies and asymptomatic hyperCKemia. A case report. Acta Myologica, 2021, 40, 105-108.	1.5	1

#	Article	IF	CITATIONS
55	Simultaneous Penile and Signet Ring Cell Bladder Carcinoma in Renal Transplant Recipient: A First Case. Scientific World Journal, The, 2009, 9, 920-923.	0.8	0
56	Advances in molecular diagnostics for mitochondrial diseases. Expert Opinion on Medical Diagnostics, 2009, 3, 557-569.	1.6	0